Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Robin M. J. M. van Geel; Emilie M. J. van Brummelen; Ferry A. L. M. Eskens; Sanne C. F. A. Huijberts; Filip Y. F. L. de Vos; Martijn P. J. K. Lolkema; Lot A. Devriese; Frans L. Opdam; Serena Marchetti; Neeltje Steeghs; Kim Monkhorst; Bas Thijssen; Hilde Rosing; Alwin D. R. Huitema; Jos H. Beijnen; Rene Bernards; Jan H. M. Schellens

doi:10.1038/s41416-020-0776-z

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Robin M. J. M. van Geel, Emilie M. J. van Brummelen, Ferry A. L. M. Eskens, Sanne C. F. A. Huijberts^*, Filip Y. F. L. de Vos, Martijn P. J. K. Lolkema, Lot A. Devriese, Frans L. Opdam^*, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, Rene Bernards, Jan H. M. Schellens

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Web of Science)

Original language	English
Pages (from-to)	1166-1174
Number of pages	9
Journal	British Journal of Cancer
Volume	122
Issue number	8
DOIs	https://doi.org/10.1038/s41416-020-0776-z
Publication status	Published - Apr 2020

Keywords

RAS
ARRY-142886
DOCETAXEL
AZD6244

Access to Document

10.1038/s41416-020-0776-zLicence: CC BY

Cite this

van Geel, R. M. J. M., van Brummelen, E. M. J., Eskens, F. A. L. M., Huijberts, S. C. F. A., de Vos, F. Y. F. L., Lolkema, M. P. J. K., Devriese, L. A., Opdam, F. L., Marchetti, S., Steeghs, N., Monkhorst, K., Thijssen, B., Rosing, H., Huitema, A. D. R., Beijnen, J. H., Bernards, R., & Schellens, J. H. M. (2020). Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. British Journal of Cancer, 122(8), 1166-1174. https://doi.org/10.1038/s41416-020-0776-z

van Geel, Robin M. J. M. ; van Brummelen, Emilie M. J. ; Eskens, Ferry A. L. M. ; Huijberts, Sanne C. F. A. ; de Vos, Filip Y. F. L. ; Lolkema, Martijn P. J. K. ; Devriese, Lot A. ; Opdam, Frans L. ; Marchetti, Serena ; Steeghs, Neeltje ; Monkhorst, Kim ; Thijssen, Bas ; Rosing, Hilde ; Huitema, Alwin D. R. ; Beijnen, Jos H. ; Bernards, Rene ; Schellens, Jan H. M. / Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. In: British Journal of Cancer. 2020 ; Vol. 122, No. 8. pp. 1166-1174.

@article{5fa67bf8ea0342d28320864e4ef83876,

title = "Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer",

keywords = "RAS, ARRY-142886, DOCETAXEL, AZD6244",

author = "{van Geel}, {Robin M. J. M.} and {van Brummelen}, {Emilie M. J.} and Eskens, {Ferry A. L. M.} and Huijberts, {Sanne C. F. A.} and {de Vos}, {Filip Y. F. L.} and Lolkema, {Martijn P. J. K.} and Devriese, {Lot A.} and Opdam, {Frans L.} and Serena Marchetti and Neeltje Steeghs and Kim Monkhorst and Bas Thijssen and Hilde Rosing and Huitema, {Alwin D. R.} and Beijnen, {Jos H.} and Rene Bernards and Schellens, {Jan H. M.}",

year = "2020",

month = apr,

doi = "10.1038/s41416-020-0776-z",

language = "English",

volume = "122",

pages = "1166--1174",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "8",

}

van Geel, RMJM, van Brummelen, EMJ, Eskens, FALM, Huijberts, SCFA, de Vos, FYFL, Lolkema, MPJK, Devriese, LA, Opdam, FL, Marchetti, S, Steeghs, N, Monkhorst, K, Thijssen, B, Rosing, H, Huitema, ADR, Beijnen, JH, Bernards, R & Schellens, JHM 2020, 'Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer', British Journal of Cancer, vol. 122, no. 8, pp. 1166-1174. https://doi.org/10.1038/s41416-020-0776-z

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. / van Geel, Robin M. J. M.; van Brummelen, Emilie M. J.; Eskens, Ferry A. L. M.; Huijberts, Sanne C. F. A.; de Vos, Filip Y. F. L.; Lolkema, Martijn P. J. K.; Devriese, Lot A.; Opdam, Frans L.; Marchetti, Serena; Steeghs, Neeltje; Monkhorst, Kim; Thijssen, Bas; Rosing, Hilde; Huitema, Alwin D. R.; Beijnen, Jos H.; Bernards, Rene; Schellens, Jan H. M.

In: British Journal of Cancer, Vol. 122, No. 8, 04.2020, p. 1166-1174.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

AU - van Geel, Robin M. J. M.

AU - van Brummelen, Emilie M. J.

AU - Eskens, Ferry A. L. M.

AU - Huijberts, Sanne C. F. A.

AU - de Vos, Filip Y. F. L.

AU - Lolkema, Martijn P. J. K.

AU - Devriese, Lot A.

AU - Opdam, Frans L.

AU - Marchetti, Serena

AU - Steeghs, Neeltje

AU - Monkhorst, Kim

AU - Thijssen, Bas

AU - Rosing, Hilde

AU - Huitema, Alwin D. R.

AU - Beijnen, Jos H.

AU - Bernards, Rene

AU - Schellens, Jan H. M.

PY - 2020/4

Y1 - 2020/4

KW - RAS

KW - ARRY-142886

KW - DOCETAXEL

KW - AZD6244

U2 - 10.1038/s41416-020-0776-z

DO - 10.1038/s41416-020-0776-z

M3 - Article

C2 - 32147669

VL - 122

SP - 1166

EP - 1174

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -

van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, de Vos FYFL, Lolkema MPJK et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. British Journal of Cancer. 2020 Apr;122(8):1166-1174. https://doi.org/10.1038/s41416-020-0776-z